These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 11076110

  • 21. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 22. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, Sato Y, Hara S, Eto T.
    Ren Fail; 2005 Dec; 27(4):361-5. PubMed ID: 16060120
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.
    Vlahakos DV, Retsa K, Kalogeropoulou S, Katsoudas S, Bacharaki D, Agroyannis B.
    Artif Organs; 2007 Dec; 31(12):892-5. PubMed ID: 17924988
    [Abstract] [Full Text] [Related]

  • 27. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [Abstract] [Full Text] [Related]

  • 28. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
    Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T, ROD21 Clinical Research Group.
    Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
    [Abstract] [Full Text] [Related]

  • 29. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT.
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK, Devlin L, Taal MW, Fluck RJ, McIntyre CW.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003.
    Weinhandl ED, Rao M, Gilbertson DT, Collins AJ, Pereira BJ.
    Am J Kidney Dis; 2007 Nov; 50(5):803-12. PubMed ID: 17954293
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Hematocrit levels and associated Medicare expenditures.
    Collins AJ, Li S, Ebben J, Ma JZ, Manning W.
    Am J Kidney Dis; 2000 Aug; 36(2):282-93. PubMed ID: 10922306
    [Abstract] [Full Text] [Related]

  • 40. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK, Slatopolsky EA, Goldberg DI.
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.